Compare Heron Therapeutics Inc (HRTX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Wayfair Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Wayfair Inc trades at $105.14 (market cap $14.31B). The key difference: Wayfair Inc is far larger — about 193.3× Heron Therapeutics Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Wayfair Inc for 8 Days on average.
| HRTX | W | |
|---|---|---|
Market Cap | $74.04M | $14.31B |
Volume | 3,668,095 | 1,595,934 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $119.05 |
52-Week Low | $0.27 | $57.40 |
Typical Hold Time | 35 Days | 8 Days |
Enterprise Value | $180.78M | $16.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Wayfair (W) trades at $104.47, down 0.93% with a bullish technical outlook. The company shows mixed fundamentals with $12.46B revenue but negative net margins, while analysts maintain a buy consensus with a $114.06 price target. Recent developments include store expansion and upcoming Q3 earnings.
The stock presents upside potential from analyst targets and operational cash flow growth, but faces risks from persistent losses and high debt. Key catalysts include Q3 earnings on November 4, 2026, and execution of the new brand platform amid competitive retail pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
